C
Charles I. Haffajee
Researcher at Beth Israel Deaconess Medical Center
Publications - 74
Citations - 3734
Charles I. Haffajee is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Amiodarone & Ventricular tachycardia. The author has an hindex of 32, co-authored 73 publications receiving 3536 citations. Previous affiliations of Charles I. Haffajee include Tufts Medical Center & University of Massachusetts Amherst.
Papers
More filters
Journal ArticleDOI
Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation.
Adam S. Fein,Alexei Shvilkin,Dhaval Shah,Charles I. Haffajee,Saumya Das,Kapil Kumar,Daniel B. Kramer,Peter Zimetbaum,Alfred E. Buxton,Mark E. Josephson,Elad Anter +10 more
TL;DR: CPAP is an important therapy in OSA patients undergoing PVI that improves arrhythmia free survival and PVI offers limited value to OSA Patients not treated with CPAP.
Journal ArticleDOI
Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy
Enio Martino,Marjorie Safran,F. Aghini-Lombardi,R Rajatanavin,M. Lenziardi,M Fay,Alessandro Pacchiarotti,Neil Aronin,Enrico Macchia,Charles I. Haffajee +9 more
TL;DR: In patients receiving chronic amiodarone therapy, clinically suspected hyperthyroidism is best confirmed by showing elevations in serum T3 or free T3 concentrations; hypothyroidistan is best diagnosed by showing an elevated serum thyrotrophin concentration.
Journal ArticleDOI
Amiodarone for refractory atrial fibrillation
Robert L. Gold,Charles I. Haffajee,George Charos,Kathy C Sloan,Stephen P. Baker,Joseph S. Alpert +5 more
TL;DR: Overall, amiodarone therapy was effective long term in 54 of the 68 patients and the presence of chronic AF for longer than 1 year was an adverse factor in maintaining normal sinus rhythm, although the success rate even in this group was relatively high (57%).
Journal ArticleDOI
Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias.
Charles I. Haffajee,John C. Love,A. T. Canada,Lawrence J. Lesko,George K. Asdourian,Joseph S. Alpert +5 more
TL;DR: The pharmacokinetics of oral amiodarone support the practice of using high loading dosages until arrhythmia suppression or apparent steady state is achieved (usually 2–4 weeks), followed by low-dose maintenance therapy for treatment of symptomatic atrial and ventricular tachyarrhythmias.
Journal ArticleDOI
Pulmonary embolism, pulmonary hemorrhage and pulmonary infarction.
James E. Dalen,Charles I. Haffajee,Joseph S. Alpert,John P. Howe,Ira S. Ockene,John A. Paraskos +5 more
TL;DR: It is suggested that obstruction of distal arteries results in pulmonary hemorrhage owing to an influx of bronchial arterial blood at systemic pressure, which causes symptoms and x-ray changes usually attributed to pulmonary infarction in patients without, but progresses to infarctions in those with, heart disease.